ARTICLE | Clinical News
GrassMATAMPL: Phase II data
July 11, 2016 7:00 AM UTC
Top-line data from the double-blind, dose-ranging, U.S. Phase II G204 trial in about 265 patients with seasonal allergic rhinoconjunctivitis showed that a recommended Phase III dose of subcutaneous Gr...